The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.

NCT01365637 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer